Carlson Capital L P Cognition Therapeutics Inc Transaction History

Carlson Capital L P

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.66 - $2.62 $122,831 - $193,866	-73,995 Reduced 34.58%	140,000 $232,000
Q1 2024 May 14, 2024	SELL	$1.78 - $2.53 $42,728 - $60,732	-24,005 Reduced 10.09%	213,995 $389,000
Q4 2023 Feb 13, 2024	SELL	$0.96 - $2.42 $49,920 - $125,840	-52,000 Reduced 17.93%	238,000 $440,000
Q3 2023 Nov 13, 2023	BUY	$1.25 - $1.9 $56,250 - $85,500	45,000 Added 18.37%	290,000 $417,000
Q2 2023 Aug 10, 2023	SELL	$1.56 - $3.38 $263 - $571	-169 Reduced 0.07%	245,000 $448,000
Q1 2023 May 12, 2023	BUY	$1.51 - $2.3 $23,056 - $35,118	15,269 Added 6.64%	245,169 $485,000
Q4 2022 Feb 14, 2023	BUY	$1.17 - $3.51 $151,983 - $455,949	129,900 Added 129.9%	229,900 $482,000
Q3 2022 Nov 14, 2022	BUY	$1.63 - $3.6 $163,000 - $360,000	100,000 New	100,000 $190,000

6.52M

Ticker CGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,710,700
Market Cap $9.99M
Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...

Get notified when there are updates to the investment portfolio of Carlson Capital L P, based on Form 13F filings with the SEC.

Stay updated on Carlson Capital L P with notifications on news.